Lenalidomide Zentiva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to the ubiquitination and degradation of transcription factors such as Ikaros and Aiolos. The result is reduced tumor cell proliferation, inhibition of new blood‑vessel formation, and enhanced activity of immune cells that target cancer.

The exact dose and schedule are set by the prescribing clinician based on the specific indication, the patient’s overall health, renal function, and any concurrent therapies. Lenalidomide is taken orally, usually once daily, but the prescriber will tailor the regimen to achieve the best therapeutic benefit while minimizing risk.

Lenalidomide is classified as Pregnancy Category X because it is known to cause severe fetal harm. It is contraindicated in pregnant women, and effective contraception must be used during treatment and for at least four weeks after the last dose. Breastfeeding is also not recommended, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Lenalidomide is a second‑generation immunomodulatory imide drug (IMiD). Compared with thalidomide, it has a more favorable side‑effect profile, especially regarding peripheral neuropathy, and offers stronger anti‑angiogenic and immune‑stimulating effects. Pomalidomide, a newer IMiD, may be used after lenalidomide failure and can provide additional potency, but each agent’s choice depends on disease stage and patient tolerance.

Lenalidomide Zentiva tablets should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original blister pack or container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally as a whole tablet, usually with or without food, according to the prescriber’s instructions. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically directed by a healthcare professional.

Serious risks include venous thromboembolism (blood clots), severe neutropenia or thrombocytopenia (dangerously low white‑blood‑cell or platelet counts), and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of infection, bleeding, or unexplained skin changes and report any concerns promptly.

Lenalidomide should not be used by pregnant women or women who could become pregnant without reliable contraception. Individuals with known hypersensitivity to lenalidomide or any of its excipients, as well as patients with uncontrolled severe infections or severe renal impairment without dose adjustment, should avoid the drug unless a specialist determines it is appropriate.